Piramal Pharma Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹2,270Cr
- +17.4% YoY
- −17.5% QoQ
- Net profit
- −₹69Cr
- Q1 FY26: −₹82 Cr
- Margin
- 8.6%
- +3.1 pp YoY
- −8.1 pp QoQ
Guidance rank: #42 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Piramal Pharma Ltd Q1 FY27 key numbers
- Revenue
- The ADC business is scaling with new acquired capacities (Riverview, Lexington), expecting meaningful revenue growth in single to low double-digit USD million range in coming years.
As stated in Piramal Pharma Ltd's Q1 FY27 earnings call transcript · published 23 Sept 2026. Reported figures, not investment advice.
The short version
CDMO business is expected to drive significant margin expansion, with a target EBITDA margin of 25% by FY30, driven largely by improved utilization at overseas facilities and a differentiated product mix including more innovator products. Piramal Pharma started FY '27 strong with 17% revenue growth and 72% EBITDA growth YoY, signaling positive momentum.
From Piramal Pharma Ltd's Q1 FY27 earnings-call transcript · updated 23 Sept 2026.
Revenue & Sales Performance
- CDMO business is expected to drive significant margin expansion, with a target EBITDA margin of 25% by FY30, driven largely by improved utilization at overseas facilities and a differentiated product mix including more innovator products. (Page 17)
- Complex hospital generics (CHG) business growth includes both organic and acquisitions (e.g., Canalog), with market share gains in various geographies, particularly ex-US, contributing to growth. The company expects continued positive momentum in CHG in FY27. (Pages 17, 12)
- Consumer healthcare business expects margin expansion over the next few years, supported by brand momentum, channel expansion, premiumization, and disciplined pricing. (Page 17, 5)
2 more points from Piramal Pharma Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Piramal Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Annual capex guidance for FY27 is USD 120 million to USD 135 million; about USD 21 million spent so far (Page 16).
- Lexington sterile injectable capacity expansion is on track for completion by end of calendar year 2027 (Page 16).
- Riverview facility expansion completed, adding commercial-scale payload-linker development and manufacturing site with advanced capabilities; less than USD 5 million invested for specific linker payload room (Pages 9 and 15).
- Combined $90 million expansion program at Riverview and Lexington strengthening integrated ADC platform, including payload-linker manufacturing and sterile fill-finish capabilities (Page 3).
2 more points from Piramal Pharma Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Piramal Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Piramal Pharma began FY27 with a stronger opening order book compared to previous periods.
- The company referenced this stronger opening order book during the last investor call.
- There may be some ups and downs in order flow between quarters depending on delivery patterns.
2 more points from Piramal Pharma Ltd's call on order book
Create a free account to keep reading this call
What the Q1 FY27 call signalled
2 of 3 strong
Piramal Pharma Ltd — Quarterly revenue & net profit
Piramal Pharma Ltd Q1 FY27 results — key figures
| ₹ Cr | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 2,270 | 1,934 | +17.4% | 2,752 | -17.5% |
| Operating profit (EBITDA) | 195 | 107 | +82.9% | 461 | -57.6% |
| Operating margin | 8.6% | 5.52% | +3.1 pp | 16.74% | -8.1 pp |
| Profit before tax | -7 | -79 | — | 43 | -117.3% |
| Net profit (PAT) | -69 | -82 | — | -9 | — |
| EPS (₹) | -0.52 | -0.61 | — | -0.07 | — |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.6K Cr, net profit ₹5 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Piramal Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjivani Paranteral (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Piramal Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Piramal Pharma Ltd Q1 FY27 results?
CDMO business is expected to drive significant margin expansion, with a target EBITDA margin of 25% by FY30, driven largely by improved utilization at overseas facilities and a differentiated product mix including more innovator products. Piramal Pharma started FY '27 strong with 17% revenue growth and 72% EBITDA growth YoY, signaling positive momentum.
What is Piramal Pharma Ltd share price analysis?
Piramal Pharma Ltd currently shows a below-average growth signal. The stock trades at a P/E of N/A with a market cap of ₹27,713 Cr. Investors should review the full earnings analysis for detailed insights.
Is Piramal Pharma Ltd planning capital expenditure?
Annual capex guidance for FY27 is USD 120 million to USD 135 million; about USD 21 million spent so far (Page 16).
Keep Piramal Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
